Son güncelleme :
19/11/2024
Diüretik   Hydrochlorothiazide  
Oral solüsyon / oral çözelti
Farmasötik preparatlar Kararlılığı Karışımlardaki stabilitesi Stabiliteyi etkileyen faktörler Uyumluluk Kaynaklar pdf
   Kimyasal yapı   

Oral solüsyon / oral çözelti
Kaynaklar   Oral solüsyon / oral çözelti   Kaynaklar : Hydrochlorothiazide  
tip yayın
2435 Dergi Allen LV, Jr, Erickson MA,
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361 Dergi Santovena A, Hernandez-Paiz Z, Farina J.B.
Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Int J Pharm 2012 ; 423: 360-364.
3399 afiş Li Y.Y, Postma D.J, Wagenaar H.W.G.
Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children.
EAHP Congress Paris 2013
3910 Dergi Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O.
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.
EJHP 2016 ; 23: 352-358.
4177 Dergi Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4198 Dergi Uriel M, Gomez-Rincon C, Marro D.
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Pharmazie 2018 73;196-201
4256 Dergi Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A.
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Pharmaceutics 2019 ;11,190:

  Mentions Légales